A Call for Gender Identity Data Collection in iPLEDGE and Increasing the Number of Isotretinoin Prescribers Among Transgender Health Providers

Abstract

Acne is a common adverse event among trans-masculine people using testosterone as masculinizing hormone therapy. Isotretinoin is the most effective medication for severe recalcitrant acne and, as such, trans-masculine people with severe acne would likely benefit from treatment with this therapy. Incorporation of gender identity-based questions in iPLEDGE registration documentation will increase information about gender-diverse patients taking isotretinoin in the United States and allow better understanding of teratogenicity risks among these patients. An increase in the number of transgender health providers registered as isotretinoin prescribers in iPLEDGE would increase access to this effective medicine and may improve outcomes in these patients.